Introduction
Familial Mediterranean fever (FMF) is a hereditary inflammatory disorder caused by a mutation in MEFV, a gene which encodes a 781-amino acid protein called pyrin . The classic clinical picture consists of recurrent febrile episodes that are usually of an acute onset, variable frequency, sometimes without a recognized triggering factor, but often arm of chromosome 16 (16p13) and was independently identified by two positional cloning consortia and four missense mutations in exon 10, namely M694V, V726A, M694I and M680I . These four mutations and E148Q in exon 2 are the most common MEFV mutations among the 59 putative mutations identified to date and are believed to be associated with the disease . Additional less common mutations have been found subsequently in exons 3, 5, 9 and 10, bringing the current total of known mutations to 23 . Exon 10 remains the major site of mutations, with a smaller cluster in exon 2 (http://fmf.igh.cnrs.fr/infevers).
There is also an autosomal dominant form of FMF (134610), which is caused by a heterozygous mutation in the MEFV gene. The FMF carrier rate can be as high as one in three in the commonly affected ethnic groups, raising the possibility of selective heterozygote advantage . Homozygous or compound heterozygous mutations in the MEFV gene result in classic familial Mediterranean fever (FMF; 249100), which shows autosomal recessive inheritance. The MEFV transcript is expressed in granulocytes that play an essential role in the inflammatory response. Pyrin, the protein encoded by the MEFV gene, has already been analyzed by crystallography [ Fig. 1 ].
Because the disease has a wide spectrum of signs and symptoms, molecular techniques are helpful tools for verification of the diagnosis. Molecular analysis of MEFV is useful in clinical practice, mainly in an atypical form of the diseases . Colchicine is the preferred drug of choice . There is a report that mutational hotspots in codons 680 and 694 are associated with severity of disease, hospital admission, early onset, high frequency of attacks, the necessity of high dose of colchicine to control attacks, and frequent occurrence of amyloidosis in untreated patients . This study is to determine the mutation frequency in the clinically diagnosed FMF patients of an Iranian population. We report here on the distribution of MEFV mutations in FMF patients among an Iranian subethnic group.
Methods Study design and patients Routine molecular diagnosis of FMF in our laboratory began in 2010. Currently there are 120 patients in the registry, 85 of whom were included in this study. The diagnosis of FMF in these patients was made according to established clinical criteria by pediatricians. Eighty-five unrelated subjects (31 males and 54 females) clinically diagnosed with FMF were recruited from university hospitals and private pediatric clinics after referral by a physician to the Department of Genetics for confirmation of diagnosis of FMF. The study was designed to determine the spectrum of mutations in the Mediterranean fever gene in an Iranian population with FMF and to consider their clinical symptoms.
Mutation Analyses A 3ml blood sample was collected from all subjects, and our method was based on the FMF strip assay (ViennaLab Diagnostics GmbH) for detecting mutations. Genomic DNA was extracted from 200µL peripheral blood samples obtained from the patients by using the "Gene extract" extraction method, and was stored at −20°C until use. Then, patients were studied using a reverse hybridization test strip-based assay Results Mutation analysis showed that identified missense mutations accounted for all of the 170 independent FMF alleles. The mutation detection protocol revealed in patients eight different previously reported mutations located in exon 10 (M680I, M694I, M694V, K695R, V726A, A744S, R761H) and exon 2 (E148Q). There aren't any mutations in exon 3 (P369S), exon 5 (F479L) and exon 10 (I692del) in our detection. The most common mutation was M694V (21%). Other mutations accounted for a further 38% of the alleles: M694I (11%), M680I (6%), E148Q (11%), V726A (4%), and R761H (5%) [ Table 1 ]. Mutations in both alleles were identified in 33 of the 85 patients (39%): seven (9%) were homozygous for the same mutation, and 26 (30%) were compound heterozygous for different combinations of the mutations. Thirty-four (40%) were found to be heterozygous for one mutation. In 18 patients (21%), no mutation could be detected. Out of the 85 patients, 67 (79%) carried at least one mutation [ Table 2 ]. The numbers of each allele in patients in whom at least one mutation was detected are shown in two groups: heterozygote and homozygote or compound heterozygote [Fig. 2] . Two rare mutations (A744S and K695R) were present at an allele frequency <1% in Zanjan, one of Azari provinces, and three mutations in exon 3 (369S), exon 5 (F479L) and exon 10 (I692del) were not detected in any of our patients [ Table 1 ].
All of the cases in this study were from different parts of Iran, mostly from Azari provinces (Turk ethnicity) (28%), north provinces (Alborz area) (25%), Tehran province (20%), and 27% of patients were from the rest of Iran. The most frequent mutations among all patients as well as the patients from Azari provinces (Turk ethnicity), north provinces (Alborz area) and Tehran provinces were M694V, while the most frequent mutations among Kurdish were M694I and among central provinces were E148Q [ Figure 3] .
The clinical characteristics of the patients were as follows: joint problems were observed in 17% and abdominal pain in 52%. Other clinical data for chest pain, peritonitis, vasculitic rash, and amyloidosis were not available in our lab registry at this time. Age of disease onset was 27% of the patients under one year old and was 35% and 38% for patients under and above 6 years old, respectively. The average age of onset among all patients was 8 years old. Almost all patients had fever and two patients had a history of amyloidosis. Thirtythree (39%) patients had a history of at least one admission to hospital. The percentages of the frequency of each mutation were almost the same among admitted versus non-admitted patients, except for E148Q mutation, which was 24% among admitted patients and 15% among non-admitted patients, and R761H mutation, which was 4.5% among admitted patients Figure 2 . Number of each allele in patients that at least one mutation was detected is shown in two groups: heterozygote and homozygote or compound heterozygote (total alleles: 170). and 11% among non-admitted patients. Among the two cases with amyloidosis, both of them were heterozygous for E148Q mutation. Thirty-nine percent of patients received drugs for treatment and the patient without detectable mutations also received treatment. We identified three adults, one with R761H homozygote mutation and two with compound heterozygote mutations of R761H/ V726A and V726A/M694V, who had the age onset of over 35 years old. The 67 patients who carry at least one mutation have classical clinical symptoms, with fever lasting from a few hours to 1 week, which was not different from the 18 patients in whom no mutations were identified. The clinical picture in all of the patients is summarized. A comparison between the phenotypic features of FMF patients and the genotypes of all patients is shown in [ Table 3 ].
Discussion
To our knowledge, this is the first comprehensive study of FMF in the Iranian population that examines the spectrum and distribution of MEFV mutations among affected individuals. In this study, we have determined the mutation frequencies of 12 common mutations in the MEFV gene in 85 Iranian FMF patients. The M694V mutation, which is found in 21% of populations, and another seven mutations were found in about 38% of Iranian FMF alleles [ Table 1 ]. Mutations in both alleles were identified in 33 of the 85 patients (39%): seven (9%) were homozygous for the same mutation, and 26 (30%) were compound heterozygous for different combinations of the mutations [ Table 2 ]. In Turkish people the mutations in both alleles were identified in 263 of the 450 patients (58.44%): 179 (39.77%) were homozygous for the same mutation, and 84 (18.66%) were compound heterozygous for different combinations of the mutations . Eighty-three (18.44%) were found to be heterozygous for one mutation and no mutation could be detected in 104 patients (23.11%). Out of the 85 patients, 67 (79%) carried at least one mutation (43 males and 24 females). While all patients carried at least one mutation, they are not expected to carry mutant chromosomes [ Table  1 , Table 2 ]. The most common mutation was M694V (21%). Other mutations accounted for a further 38% of the alleles: M694I (11%), M680I (6%), E148Q (11%), V726A (4%), and R761H (5%). Three mutations in exon 3 (P369S), exon 5 (F479L) and exon 10 (I692del) were not detected in any of our patients [ Table 1 ]. The third, fourth, fifth and sixth commonest mutations in our study were E148Q (11%), M680I (6%), V726A (4%) and R761H (5%), respectively. These results were near to the Algerian study in which the third, fourth and fifth commonest mutations were E148Q (12%), A744S (10%) and M680I (8%), respectively . But A744S was present at an allele frequency <1% in Zanjan, one of the Azari provinces. Here, mutation analysis showed that six identified missense mutations accounted for 58% of the 180 independent FMF alleles [ Table 1 ]. This study confirms that M694V is the most common MEFV mutation in the Iranian population, but shows a new spectrum and distribution that are different from what have previously been reported.
In our data, E148Q mutations show 30% under one year of disease onset, but show 14% above one year of disease onset, suggesting that E148Q mutations act as an early onset disease factor and show their deleterious effect on MEFV gene function. The E148Q mutation is a dominant inheritance (AD) pattern with reduced penetrance most of the time. In future functional studies, we should provide answers to the questions: What is the biologic basis of the heterozygote ad-vantage?, What are the modifier genes? and How does amyloidosis work?
Also, allele frequency of each geographic area in Iran needs to perform more analyses in our future plan. The proportion of unknown alleles (41%) in our study [ Table 1 ], which are carrying rare mutations, needs to be analyzed for unscreened exons.
Conclusion
In conclusion, our study describes the MEFV mutational spectrum and distribution in the Iranian population by studying FMF patients and controls and employing a comprehensive mutation detection strategy. Our future strategy for mutation analysis is to perform detection analysis for all unknown as well as heterozygous patients by sequencing the promoter region (~500 bp upstream of the ATG translation), the entire coding sequence, and all exon-intron boundaries (50 bp of the exon flanking intronic sequences) in forward and reverse directions after PCR amplification.
